Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 203Brain Neoplasms 94Gliosarcoma 93Glioma 88Central Nervous System Neoplasms 78Astrocytoma 66Oligodendroglioma 45Melanoma 37Medulloblastoma 18Neuroblastoma 17Neoplasm Metastasis 14Ependymoma 13Neoplasms 10Choroid Plexus Neoplasms 10Sarcoma 9Recurrence 9Optic Nerve Glioma 9Familial ependymoma 9Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Lung Neoplasms 8Spinal Cord Neoplasms 7Breast Neoplasms 7Uveal Melanoma 6Sarcoma, Ewing 6Rhabdoid Tumor 6Pinealoma 6Neuroectodermal Tumors, Primitive 6Unspecified Adult Solid Tumor, Protocol Specific 5Small Cell Lung Carcinoma 5

Interventions

Temozolomide 1Nivolumab 1Lomustine 1Ipilimumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Newly Diagnosed High Grade Glioma × Temozolomide × Clear all
NCT03425292 2023-11-08

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Saint John's Cancer Institute

Phase 1 Completed
49 enrolled
CNS

Newly Diagnosed High Grade Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡